Companies / Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

Nasdaq: MBRXCIK 1659617HOUSTON, TX

Financials · FY2025

Revenue$0
Net income$-33.56M
Total debt—
Cash$7.26M
Diluted EPS—
Shares outstanding5.3M

Ownership

5.3M shares outstanding · as of May 7, 2026
0.01%Insiders
Ownership
Insiders0.01%753
Institutions2.11%112,407
Public float97.88%5,223,190

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 1

View all →
Insider% of sharesShares
Picker Donald HChief Science Officer
0.01%753

Institutional holders 17

View all →
HolderValue% of shares
Citadel Advisors LLC$109.5K0.62%
Jane Street Group, LLC$74.6K0.42%
Geode Capital Management, LLC$74.0K0.61%
Vanguard Group Inc$51.5K0.29%
UBS Group AG$19.4K0.11%
Tower Research Capital LLC (TRC)$4.6K0.03%
EFG International AG$1.4K<0.01%
BlackRock, Inc.$1.4K<0.01%
Pinnacle Wealth Planning Services, Inc.$930<0.01%
Rockefeller Capital Management L.P.$722<0.01%

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$39.4K+17K
+113.56%
32,329
0.61% of shares
low
Q2 2026
as of
Pinnacle Wealth Planning Services, Inc.
13F manager
ExitCommon Stock$-930-281
-100.00%
0
low
Q4 2025
as of
Bank of America Corp /De
13F manager
NewCommon Stock$119+36
36
<0.01% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
TrimCommon Stock$-11-4
-0.81%
491
<0.01% of shares
low
Q4 2025
as of
Danske Bank A/S
13F manager
NewCommon Stock$7+2
2
<0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
MBRXCommon StockEquity60855D408BBG00B9T47L9